Research Analyst Related Topics 
The Pharma Data
AUGUST 20, 2020
The latest results underscore that large pharma companies are making a “strategic retreat from some of their older drugs,” in China, ICBC International Research analyst Zhang Jialin said, as quoted by Bloomberg; instead, they’re focusing on growing market share for newer medicines. It’s not a completely unforeseen shift, though.
Pharmaceutical Technology
MARCH 17, 2023
Over the last twenty years, there has been a major rise in risk sharing agreements in the pharmaceutical space, said Alex Watt, GlobalData’s principal research analyst, at a recent webinar on the same topic.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
APRIL 13, 2021
Kyle Gaan, a research analyst at GFI said in the same press release, “2020 was a breakout year for plant-based foods across the store. The growth can also be attributed to the placement of plant-based meat in the meat section, with refrigerated plant-based meat sales growing twice as fast as their frozen counterparts.
Pharmaceutical Technology
JANUARY 27, 2023
Designing risk sharing agreements Overall however, this warranty program is similar to previous performance-based risk sharing agreements, says Alex Watt, principal research analyst on GlobalData’s Price Intelligence team. GlobalData is the parent company of Pharmaceutical Technology.
The Pharma Data
DECEMBER 31, 2020
Prior to that, Zhang was an equity research analyst at UBS in New York, where he covered the Major and Specialty Pharmaceutical Sector. Zhang will be responsible for all aspects of financial management and work closely with Novotech Holdings’ executive team to support the growth of the business across Asia.
XTalks
JUNE 9, 2022
Tirzepatide’s continuing stellar trial results as a weight loss injection have industry analysts putting up big predictions for the drug, particularly as a rival to Novo’s obesity drug Wegovy (tirzepatide is currently only approved for the treatment of type 2 diabetes under the trade name Mounjaro). billion in sales by 2026.
The Pharma Data
DECEMBER 28, 2020
Prior to that, Dr. Zhang was an equity research analyst at UBS in New York , where he covered the Major and Specialty Pharmaceutical Sector. in its healthcare practice and conducted postdoctoral research in diabetes-related drug development at Boston University’s School of Medicine.
Expert insights. Personalized for you.
52 
Let's personalize your content